Insilico Medicine, Eli Lilly announce AI-driven drug discovery collaboration

Insilico Medicine announced a research collaboration with Eli Lilly (LLY) that the two parties will combine Insilico’s Pharma.AI platforms with Lilly’s development and disease expertise to jointly discover and advance innovative therapies. “Insilico will utilize its validated Pharma.AI platform and deep drug discovery expertise to generate, design, and optimize candidate compounds against targets defined under the agreement. Insilico is eligible to receive over $100 million including an upfront, milestone payments, and tiered royalties on net sales upon commercialization of any resulting drug products… The collaboration represents a further deepening of the partnership between the two companies, which originated with the AI-based software licensing agreement in 2023,” the companies stated. Alex Zhavoronkov, PhD, Founder and Co-CEO of Insilico Medicine, said: “We are delighted to collaborate with Lilly, a global leader in the pharmaceutical industry, renowned for its commitment to medical innovation. Lilly has been a valued user of our Pharma.AI software suite, and this expanded collaboration further recognizes Insilico’s AI-driven drug discovery capabilities while strengthening our longstanding partnership. By joining forces, we are accelerating the development of transformative therapies to address urgent patient needs worldwide.”